Hypofractioned Radiation Therapy in the Treatment of Partial Breast: 30 Gy in Five Consecutive Fractions

Sara Terenzi, Rosaria Barbarino, Maria Daniela Falco, Daniela di Cristino, Luana Di Murro, Dania Janniello, Gianluca Ingrosso, Alessandra Murgia, Grazia Tortorelli, Barbara Tolu, Riccardo Santoni

Department of Diagnostic Imaging, Molecular Imaging, Interventional Radiology and Radiotherapy, Tor Vergata University General Hospital, Viale Oxford, Rome, Italy..

DOI: 10.4236/jct.2012.36150                

Abstract

Background and Purpose: Recent prospective studies have explored the partial breast irradiation (PBI) for patients with early-stage breast cancer using different technical approaches. The purpose of this study is to explore feasibility, tumor control and acute and late toxicity of a specific hypo-fractionated 3D-CRT when treating postmenopausal patients with early breast cancer with partial breast irradiation, using five fractions in five consecutive days. Materials and Methods: Ten patients, aged ≥ 70 underwent breast conservative surgery for invasive breast carcinoma with a complete microscopic resection; no lymphovascular invasion was found and negative axillary node status was assessed. Metal clips were positioned in the surgical bed at the time of surgery. All of the patients provided an informed consent for breast irradiation. Seven patients received Tamoxifen. Of the ten patients, five were treated for left breast disease, and five for right breast disease. The dose fractionation schedule was 3000 cGy delivered to the isocenter in 5 fractions (600 cGy/fr) using 6 MV photons. According to the linear quadratic model and an α/β ratio of 4 Gy this prescription is equivalent to 50 Gy in a standard 2-Gy fractionation schedule. Patients were treated in the supine position. A comercial breast board was used as immobilization device in order to keep the arms of the patient raised. The clinical target volume (CTV) was drawn with a uniform 1-cm three-dimensional margin around the surgical clips. The CTV was limited to 3 mm from the skin surface and 3 mm from the lung-chest wall interface. A three-dimensional margin was added to the CTV to obtain the planning target volume (PTV). The ipsilateral and controlateral breast, the ipsilateral and controlateral lung, heart and spinal cord were contoured as organs at risk (OAR). The treatment was developed using Precise Plan Treatment Planning System and four no-coplanar fields. The constraints used have been: uninvolved breast (ipsilateral breast-PTV): V15 ≤ 50%; heart: V3 ≤ 10%; ipsilateral lung: V10 ≤ 20%; controlateral lung: V5 ≤ 10% and controlateral breast: maximum dose ≤ 1 Gy. We required PTV coverage of ≥ 90%. Patient set-up was verified every day before treatment using portal images. No tumour bed boost was delivered. Clinical assessments of early normal tissue reaction were carried out every day during radiotherapy and 10 days after the end of the treatment. After radiotherapy, we visited all patients every 3 months during the first 2 years and every six month thereafter. Frontal and lateral pictures of the breast were taken on the first day of treatment (baseline), at the end of treatment, 10 days after the end of treatment and at the first follow-up. Any change in breast appearance compared with the baseline picture was scored on a four-point RTOG for acute and late radiation morbidity scoring scale. Results: No local or distant recurrences was observed and then confirmed by mammograms performed every year and breast ultrasound performed every six months. For acute and late toxicity, only 2 patients developed acute effects at the end of the treatment. Conclusion: The clinical outcomes observed in ten patients demonstrate a good feasibility of the schedule adopted both in terms of tumour control and acute and late toxicity, with good cosmetics results. Long term follow-up and a large number of patients will be needed for full evaluation.

Keywords

Breast Cancer; Partial Breast Irradiation; Hypofractioned

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	M. Clarke, R. Collins, S. Darby, C. Davies, P. Elphinstone, E. Evans, et al., “Effects of Radiotherapy and of Differences in the Extent of Surgery for Early Breast Cancer on Local Recurrence and 15-Years Survival: An Overview of the Randomised Trials,” Lancet, Vol. 366, No. 9503, 2005, pp. 2087-2106.
[2]	S. C. Darby, P. McGale, C. W. Taylor and R. Peto, “Long-Term Mortality from Heart Disease and Lung Cancer after Radiotherapy for Early Breast Cancer: Prospective Cohort Study of about 300,000 Women in US SEER Cancer Registries,” Lancet Oncology, Vol. 6, 2005, pp. 557-565. doi:10.1016/S1470-2045(05)70251-5
[3]	A. Fourquet, F. Campana, B. Zafrani, V. Mosseri, P. Vielh, J. C. Durand, et al., “Prognostic Factors of Breast Recurrence in the Conservative Management of Early Breast Cancer: A 25-Year Follow-Up,” International Journal of Radiation Oncology*Biology*Physics, Vol. 17, No. 4, 1989, pp. 719-725. doi:10.1016/0360-3016(89)90057-6
[4]	J. Boyages, A. Recht, J. L. Connolly, S. J. Schnitt, R. Gelman, H. Kooy, et al., “Early Breast Cancer: Predictors of Breast Recurrence for Patients Treated with Conservative Surgery and Radiation Therapy,” Radiotherapy & Oncology, Vol. 19, No. 1, 1990, pp. 29-41. doi:10.1016/0167-8140(90)90163-Q
[5]	J. M. Kurtz, J. M. Spitalier, R. Amalric, H. Brandone, Y. Ayme, J. Jacquemier, et al., “The Prognostic Significance of Late Local Recurrence after Breast-Conserving Therapy,” International Journal of Radiation Oncology*Biology*Physics, Vol. 18, No. 1, 1990, pp. 87-93. doi:10.1016/0360-3016(90)90271-K
[6]	B. Fowble, L. J. Solin, D. J. Schultz, J. Rubenstein, R. L. Goodman et al., “Breast Recurrence Following Conservative Surgery and Radiation: Pattern of Failure, Prognosis, and Pathologic Findings from Mastectomy Specimens with Implications for Treatment,” International Journal of Radiation Oncology*Biology*Physics, Vol. 19, 1990, pp. 833-842.
[7]	R. M. Clark, P. B. McCulloch, M. N. Levine, M. Lipa, R. H. Wilkinson, L. J. Mahoney, et al., “Randomized Clinical Trial to Assess the Effectiveness of Breast Irradiation Following Lumpectomy and Axillary Dissection for Node Negative Breast Cancer,” Journal of the National Cancer Institute, Vol. 84, No. 9, 1992, pp. 683-689. doi:10.1093/jnci/84.9.683
[8]	I. Gage, A. Recht, R. Gelman, A. J. Nixon, B. Silver, B. A. Bornstein, et al., “Long-Term Outcome Following Breast-Conserving Surgery and Radiation Therapy,” International Journal of Radiation Oncology*Biology* Physics, Vol. 33, No. 2, 1995, pp. 245-251. doi:10.1016/0360-3016(95)02001-R
[9]	G. Liljegren, L. Holmberg, J. Bergh, A. Lindgren, L. Tabár, H. Nordgren, et al., “10-Year Results after Sector Resection with or without Postoperative Radiotherapy for Stage I Breast Cancer: A Randomized Trial,” Journal of Clinical Oncology, Vol. 17, No. 8, 1999, pp. 2326-2333.
[10]	E. Touboul, L. Buffat, Y. Belkacémi, J. P. Lefranc, S. Uzan, P. Lhuillier, et al., “Local Recurrences and Distant Metastases after Breast-Conserving Surgery and Radiation Therapy for Early Breast Cancer,” International Journal of Radiation Oncology*Biology*Physics, Vol. 43, No. 1, 1999, pp. 25-38. doi:10.1016/S0360-3016(98)00365-4
[11]	T. E. Smith, D. Lee, B. C. Turner, D. Carter and B. G. Haffty, “True Recurrence vs New Primary Ipsilateral Breast Tumor Relapse: An Analysis of Clinical and Pathologic Differences and Their Implications in Natural History, Prognosis, and Therapeutic Management,” International Journal of Radiation Oncology*Biology* Physics, Vol. 48, No. 5, 2000, pp. 1281-1289. doi:10.1016/S0360-3016(00)01378-X
[12]	U. Veronesi, E. Marubini, L. Mariani, V. Galimberti, A. Luini, P. Veronesi, et al., “Radiotherapy after Breast-Conserving Surgery in Small Breast Carcinoma: Long-Term Results of Randomized Trial,” Annals of Oncology, Vol. 12, No. 7, 2001, pp. 997-1003. doi:10.1023/A:1011136326943
[13]	E. Huang, T. A. Buchholz, F. Meric, S. Krishnamurthy, N. Q. Mirza, F. C. Ames, et al., “Classifying Local Disease Recurrences after Breast Conservation Therapy Based on Location and Histology: New Primary Tumors Have More Favorable Outcomes than True Local Disease Recurrences,” Cancer, Vol. 95, No. 10, 2002, pp. 2059-2067. doi:10.1002/cncr.10952
[14]	J. M. Kurtz, R. Amalric, H. Brandone, Y. Ayme, J. Jacquemier, J. C. Pietra, et al., “Local Recurrence after Breast-Conserving Surgery and Radiotherapy. Frequency, Time Course, and Prognosis,” Cancer, Vol. 63, No. 10, 1989, pp. 1912-1917. doi:10.1002/1097-0142(19890515)63:10<1912::AID-CNCR2820631007>3.0.CO;2-Y
[15]	T. E. Smith, D. Lee, B. C. Turner, D. Carter, B. G. Haffty, “True Recurrence vs New Primary Ipsilateral Breast Tumor Relapse: An Analysis of Clinical and Pathologic Differences and Their Implications in Natural History, Prognoses, and Therapeutic Management,” International Journal of Radiation Oncology*Biology*Physics, Vol. 48, 2000, pp. 1281-1289. doi:10.1016/S0360-3016(00)01378-X
[16]	L. Cionini, P. Pacini and S. Marzano, “Exclusive Brachy-therapy after Conservative Surgery in Cancer of the Breast,” Lyon Chirurgical, Vol. 89, 1993, p. 128.
[17]	L. Krishnan, W. R. Jewell, O. W. Tawfik, E. C. Krishnan, “Breast Conservation Therapy with Tumor Bed Irradiation Alone in a Selected Group of Patients with Stage I Breast Cancer,” Breast Journal, Vol. 7, No. 2, 2001, pp. 91-96. doi:10.1046/j.1524-4741.2001.007002091.x
[18]	F. A. Vicini, K. L. Baglan, L. L. Kestin, C. Mitchell, P. Y. Chen, R. C. Frazier, et al., “Accelerated Treatment of Breast Cancer,” Journal of Clinical Oncology, Vol. 19, No. 7, 2001, pp. 1993-2001.
[19]	D. W. Arthur, D. Koo, R. D. Zwicker, S. Tong, H. D. Bear, B. J. Kaplan, et al., “Partial Breast Brachytherapy after Lumpectomy: Low-Dose-Rate and High-Dose-Rate Experience,” International Journal of Radiation Oncology*Biology*Physics, Vol. 56, No. 3, 2003, pp. 681-689. doi:10.1016/S0360-3016(03)00120-2
[20]	C. Leonard, D. Carter, J. Kercher, K. Howell, P. Henkenberns, M. Tallhamer, et al., “Prospective Trial of Accelerated Partial Breast Intensity-Modulated Radiotheratpy,” International Journal of Radiation Oncology*Biology*Physics, Vol. 67, No. 5, 2007, pp. 1291-1298. doi:10.1016/j.ijrobp.2006.11.016
[21]	K. L. Baglan, M. B. Sharpe, D. Jaffray, R. C. Frazier, J. Fayad, L. L. Kestin, et al., “Accelerated Partial Breast Irradiation Using 3D Conformal Radiation Therapy (3D-CRT),” International Journal of Radiation Oncology* Biology*Physics, Vol. 55, No. 4, 2003, pp. 302-311. doi:10.1016/S0360-3016(02)03811-7
[22]	S. C. Formenti, M. T. Truong, J. D. Goldberg, V. Mukhi, B. Rosenstein, D. Roses, et al., “Prone Accelerated Partial Breast Irradiation after Breast-Conserving Surgery: Preliminary Clinical Results and Dose-Volume Histogram Analysis,” International Journal of Radiation Oncology* Biology*Physics, Vol. 60, No. 2, 2004, pp. 493-504. doi:10.1016/j.ijrobp.2004.04.036
[23]	L. Livi, F. B. Buonamici, G. Simontacchi, V. Scotti, M. Fambrini, A. Compagnucci, et al., “Accelerated Partial Breast Irradiation with IMRT: New Tecnical Approach and Interim Analysis of Acute Toxicity in a Phase III Randomized Clinical Trial,” International Journal of Radiation Oncology*Biology*Physics, Vol. 77, No. 2, 2010, pp. 509-515. doi:10.1016/j.ijrobp.2009.04.070
[24]	J. V. Antonucci, M. Wallace, N. S. Goldstein, L. Kestin, P. Chen, P. Benitez, et al., “Differences in Patterns of Failure in Patients Treated with Accelerated Partial Breast Irradiation versus Whole-Breast Irradiation: A Matched-Pair Analysis with 10-Year Follow-Up,” International Journal of Radiation Oncology*Biology*Physics, Vol. 74, No. 2, 2009, pp. 447-452. doi:10.1016/j.ijrobp.2008.08.025
[25]	B. Fisher, S. Anderson, J. Bryant, R. G. Margolese, M. Deutsch, E. R. Fisher, et al., “Twenty-Year Follow-Up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer,” New England Journal of Medicine, Vol. 347, No. 16, 2002, pp. 1233-1241. doi:10.1056/NEJMoa022152
[26]	J. Fowler, “The Linear-Quadratic Formula and Progress in Fractionated Radiotherapy,” British Journal of Radiology, Vol. 62, No. 740, 1989, pp. 679-694. doi:10.1259/0007-1285-62-740-679
[27]	T. J. Whelan, J. P. Pignol, M. N. Levine, J. A. Julian, R. MacKenzie, S. Parpia, et al., “Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer,” New England Journal of Medicine, Vol. 362, No. 6, 2010, pp. 513-520. doi:10.1056/NEJMoa0906260
[28]	START Trialists’ Group, S. M. Bentzen, R. K. Agrawal, E. G. Aird, J. M. Barrett, P. J. Barrett-Lee, J. M. Bliss, J. Brown, J. A. Dewar, H. J. Dobbs, J. S. Haviland, P. J. Hoskin, P. Hopwood, P. A. Lawton, B. J. Magee, J. Mills, D. A. Morgan, J. R. Owen, S. Simmons, G. Sumo, M. A. Sydenham, K. Venables and J. R. Yarnold, “The UK Standardization of Breast Radiotherapy (START) Trial a of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: A Randomized Trial,” Lancet Oncology, Vol. 9, No. 4, 20
[29]	START Trialists’ Group, S. M. Bentzen, R. K. Agrawal, E. G. Aird, J. M. Barrett, P. J. Barrett-Lee, S. M. Bentzen, J. M. Bliss, J. Brown, J. A. Dewar, H. J. Dobbs, J. S. Haviland, P. J. Hoskin, P. Hopwood, P. A. Lawton, B. J. Magee, J. Mills, D. A. Morgan, J. R. Owen, S. Simmons, G. Sumo, M. A. Sydenham, K. Venables, J. R. Yarnold, “The UK Standardization of Breast Radiotherapy (START) Trial B of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: A Randomized Trial,” Lancet, Vol. 371, No.
[30]	L. Livi, M. Stefanacci, S. Scoccianti, D. Dicosmo, S. Borghesi, F. Nosi, et al., “Adjuvant Hypofractionated Radiation Therapy for Breast Cancer after Conserving Surgery,” Clinical oncology (Royal College of Radiologists), Vol. 19, No. 2, 2007, pp. 120-124. doi:10.1016/j.clon.2006.11.006
[31]	FAST Trialists Group, R. K. Agrawal, A. Alhasso, P. J. Barrett-Lee, J. M. Bliss, P. Bliss, D. Bloomfield, J. Bowen, A. M. Brunt, E. Donovan, M. Emson, A. Goodman, A. Harnett, J. S. Haviland, R. Kaggwa, J. P. Morden, A. Robinson, S. Simmons, A. Stewart, M. A. Sydenham, I. Syndikus, J. Tremlett, Y. Tsang, D. Wheatley, K. Venables and J. R. Yarnold, “First Results of the Randomised UK FAST Trial of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer (CRUKE/ 04/015),” Radiotherapy and Oncology,
[32]	S. Martin, M. Mannino, A. Rostom, D. Tait, E. Donovan, S. Eagle, et al., “Acute Toxicity and 2-Years Adverse Effects of 30 Gy in Five Fractions over 15 Days to Whole Breast after Local Excision of Early Breast Cancer,” Clinical oncology (Royal College of Radiologists), Vol. 20, No. 7, 2008, pp. 502-505. doi:10.1016/j.clon.2008.04.020
[33]	G. W. Barendsen, “Dose Fractionation, Dose Rate and Iso-Effect Relationship for Normal Tissue Responses,” International Journal of Radiation Oncology*Biology* Physics, Vol. 8, 1982, pp. 1981-1997. doi:10.1016/0360-3016(82)90459-X
[34]	G. G. Steel, J. M. Deacon, G. M. Duchesne, A. Horwich, L. R. Kelland and J. H. Peacock, “The Dose-Rate Effect in Human Tumout Cells,” Radiotherapy and Oncology, Vol. 9, No. 4, 1987, pp. 299-310. doi:10.1016/S0167-8140(87)80151-2
[35]	Y. Yamada, I. Ackerman, E. Franssen, R. G. MacKenzie and G. Thomas, “Does the Dose Fractionation Schedule Influence Local Control of Adjuvant Radiotherapy for Early-Stage Breast Cancer?” International Journal of Radiation Oncology*Biology*Physics, Vol. 44, No. 1, 1999, pp. 99-104. doi:10.1016/S0360-3016(98)00507-0
[36]	H. D. Thames, S. M. Bentzen, I. Turesson, M. Overgaard and W. Van den Bogaert, “Time-Dose Factors in Radiotherapy: A Review of the Human Data,” Radiotherapy and Oncology, Vol. 19, No. 3, 1990, pp. 219-235. doi:10.1016/0167-8140(90)90149-Q
[37]	I. Turesson and H. D. Thames, “Repair Capacity and Kinetics of Human Skin during Fractionated Radiotherapy: Erythema, Desquamation, and Telangiectasia after 3 and 5 Year’s Follow-Up,” Radiotherapy and Oncology, Vol. 15, No. 2, 1989, pp. 169-188. doi:10.1016/0167-8140(89)90131-X
[38]	J. O. Archambeau, R. Pezner and T. Wasserman, “Pathophysiology of Irradiated Skin and Breast,” International Journal of Radiation Oncology*Biology*Physics, Vol. 31, No. 5, 1995, pp. 1171-1185. doi:10.1016/0360-3016(94)00423-I
[39]	E. L. Travis and S. L. Tucker, “Isoeffect Models and Fractionated Radiation Therapy,” International Journal of Radiation Oncology*Biology*Physics, Vol. 13, No. 2, 1987, pp. 283-287. doi:10.1016/0360-3016(87)90141-6
[40]	R. G. Dale, “Time-Dependent Tumour Repopulation Factors in Linear-Quadratic Equation: Implication for Treatment Strategies,” Radiotherapy and Oncology, Vol. 15, No. 4, 1989, pp. 371-381. doi:10.1016/0167-8140(89)90084-4
[41]	J. H. Matthews, B. E. Meeker and J. D. Chapman, “Response of Human Tumor Cell Lines in Vitro for Fractionated Radiation,” International Journal of Radiation Oncology*Biology*Physics, Vol. 16, 1989, pp. 133-138. doi:10.1016/0360-3016(89)90020-5
[42]	P. D. Stanton, T. G. Cooke, G. Forster, D. Smith and J. J. Going, “Cell Kinetics in Vivo of Human Breast Cancer,” British Journal of Surgery, Vol. 83, No. 1, 1996, pp. 98-102. doi:10.1002/bjs.1800830130
[43]	K. Haustermans, J. Fowler, K. Geboes, M. R. Christiaens, A. Lerut and E. van der Schueren, “Relationshio between Potential Doubling Time (Tpot), Labeling Index and Duration of DNA Synthesis in 60 Esophageal and 35 Breast Tumors: Is It Worthwhile to Measure Tpot?” Radiotherapy and Oncology, Vol. 46, No. 2, 1989, pp. 157-167. doi:10.1016/S0167-8140(97)00164-3